Unlocking Opportunities in the Exocrine Pancreatic Insufficiency Market: 2025-2034 Forecast Report

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Exocrine Pancreatic Insufficiency Industry Market Size Be by 2025?
The market for exocrine pancreatic insufficiency has experienced robust growth recently, with its size forecasted to increase from $2.59 billion in 2024 to $2.76 billion in 2025, depicting a compound annual growth rate (CAGR) of 6.6%. Factors contributing to this growth over the historical period include heightened awareness and diagnoses, an upsurge in digestive disorders, an aging population, reduced pancreatic function, and a surge in gastrointestinal surgeries.

What's the Long-Term Growth Forecast for the Exocrine Pancreatic Insufficiency Market Size Through 2029?
Anticipated to experience substantial growth in the coming years, the market size for exocrine pancreatic insufficiency is projected to escalate to $3.58 billion by 2029, boasting a compound annual growth rate (CAGR) of 6.7%. The anticipated growth within this period can be ascribed to the consistent expansion in awareness and screening initiatives, a growing aged population, increasing chronic disease prevalence, enhanced patient healthcare accessibility, and investments in digestive health research. Telehealth and digital health solutions, collaborative research efforts, a concentrated effort on pediatric epi, advancements in regulatory processes and expedited designations, market expansion into burgeoning economies, and progress in healthcare infrastructure are major trends to look forward to within this forecast duration.

View the full report here:
https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

What Are the Key Growth Drivers Fueling the Exocrine Pancreatic Insufficiency Market Expansion?
An increase in chronic diseases is set to drive the expansion of the exocrine pancreatic insufficiency market. Chronic diseases are long-lasting medical conditions that remain for an extended period, typically longer than three months. The prolonged existence of these diseases can heighten the risk of other complications like exocrine pancreatic insufficiency, advancing the need for better management of chronic conditions through medical interventions and therapies and potentially extending individual lifespans. For instance, the World Health Organization reported in September 2023 that worldwide, 41 million deaths annually are according to chronic diseases or non-communicable diseases (NCDs), accounting for 74%. Hence, the surge in chronic diseases highlights a key driver of the exocrine pancreatic insufficiency market growth. Exocrine Pancreatic Insufficiency Market Driver: Skyrocketing Diabetes Cases Spur Growth Of Exocrine Pancreatic Insufficiency Market

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13107&type=smp

What Are the Key Trends Driving Exocrine Pancreatic Insufficiency Market Growth?
Leading companies in the exocrine pancreatic insufficiency market are concentrating their efforts on establishing patient advocacy networks such as extensive nutritional counselling to provide all-encompassing nutritional advice and assistance. The intent behind these actions is to augment awareness, knowledge, and management of the ailment among those impacted. Thorough nutritional counselling is a fully integrated strategy that personalizes diet advice based on the person's needs, health status, and lifestyle. It prioritizes education, meal preparation, and enduring habits to boost general health. For example, Nestlé Health Science, a nutrition company based in Switzerland, introduced a GLP-1 nutrition support platform in June 2024. The GLP-1 nutrition support platform by Nestlé Health Science provides custom-fit nutritional advice and professional assistance for people using GLP-1 medicines, with an emphasis on maintaining muscle mass, digestive tract health, and overall wellbeing. The primary goal is to strengthen users in managing their weight by addressing their specific dietary requirements and nurturing a supportive community.

How Is the Exocrine Pancreatic Insufficiency Market Segmented?
The exocrine pancreatic insufficiency market covered in this report is segmented -

1) By Treatment: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Other Treatments
2) By Diagnosis: Imaging Tests, Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), Other Types
3) By Symptoms: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End Users: Hospitals, Specialty Clinics, Homecare

Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Enteric-Coated Capsules, Non-Enteric-Coated Capsules, Powder Formulations
3) By Other Treatments: Medications, Surgical Interventions, Supportive Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13107&type=smp

Which Companies Are Leading the Charge in Exocrine Pancreatic Insufficiency Market Innovation?
Major companies operating in the exocrine pancreatic insufficiency market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Medtronic PLC, Eli Lilly and Company, Gilead Sciences Inc., Nestle Health Science S.A., Allergan PLC, Chiesi Farmaceutici S.p.A., Wockhardt Ltd., Amryt Pharma PLC, Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, Aimmune Therapeutics Inc., Digestive Care Inc., Enzymedica Inc., Vivus Inc., Alcresta Therapeutics Inc., Cilian AG, Perseo Pharma AG, Enzyme Development Corporation, First Wave BioPharma Inc., Synspira Therapeutics

Which Regions Are Leading the Global Exocrine Pancreatic Insufficiency Market in Revenue?
North America was the largest region in the exocrine pancreatic insufficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13107

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.